sRAGE alleviates SARS-CoV-2-induced pneumonia in hamster  

作　　者：Xiuqin Zhang Dan Li Rui Sun Xinli Hu Zhiqi Song Xiaotian Ni Hua Zhu Tiannan Guo Chuan Qin Rui-Ping Xiao 

机构地区：[1]Institute of Molecular Medicine,College of Future Technology,Peking University,Beijing,Chino [2]Key Laboratory of Human Disease Comparative Medicine of National Health Commission of the People’s Republic of China,Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases,Institute of Laboratory Animal Science,Chinese Academy of Medical Sciences and Comparative Medicine Center,Peking Union Medical College,Beijing,China [3]Westlake Laboratory of Life Sciences and Biomedicine,Key Laboratory of Structural Biology of Zhejiang Province,School of Life Sciences,Westlake University,Hangzhou,China

出　　处：《Signal Transduction and Targeted Therapy》2022年第3期610-612,共3页信号转导与靶向治疗（英文）

基　　金：This study was supported by grants from the National Key R&D Program of China(2018YFA0507600 and 2018YFA0801405);the National Natural Science Foundation of China(81970690).

摘　　要：Dear Editor Since last year,the most demanding task of the global pharmaceutical community has been focused on the development of strategies to treat coronavirus disease 2019(COVID-19).To date,several vaccines have been developed and already demonstrated their efficacy in reducing the incidence of COVID-19.1 However,the development of drugs treating COVID-19 is lagging far behind,and all the current treatment regimens have their limitations.

关 键 词：DRUGS REGIMEN PNEUMONIA 

分 类 号：R563.1[医药卫生—呼吸系统]